Skip to main content
PMC home page
Molecular and Cellular Biology logoLink to Molecular and Cellular Biology
. 1997 Jan;17(1):427–435. doi: 10.1128/mcb.17.1.427

Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis.

R O'Connor 1, A Kauffmann-Zeh 1, Y Liu 1, S Lehar 1, G I Evan 1, R Baserga 1, W A Blättler 1
PMCID: PMC231767  PMID: 8972223

Abstract

Using a series of insulin-like growth factor I (IGF-I) receptor mutants, we have attempted to define domains required for transmitting the antiapoptotic signal from the receptor and to compare these domains with those required for mitogenesis or transformation. In FL5.12 cells transfected with wild-type IGF-I receptors, IGF-I affords protection from interleukin 3 withdrawal but is not mitogenic. An IGF-I receptor lacking a functional ATP binding site provided no protection from apoptosis. However, receptors mutated at tyrosine residue 950 or in the tyrosine cluster (1131, 1135, and 1136) within the kinase domain remained capable of suppressing apoptosis, although such mutations are known to inactivate transforming and mitogenic functions. In the C terminus of the IGF-I receptor, two mutations, one at tyrosine 1251 and one which replaced residues histidine 1293 and lysine 1294, abolished the antiapoptotic function, whereas mutation of the four serines at 1280 to 1283 did not. Interestingly, receptors truncated at the C terminus had enhanced antiapoptotic function. In Rat-1/ c-MycER fibroblasts, the Y950F mutant and the tyrosine cluster mutant could still provide protection from c-Myc-induced apoptosis, whereas mutant Y1250/1251F could not. These studies demonstrate that the domains of the IGF-I receptor required for its antiapoptotic function are distinct from those required for its proliferation or transformation functions and suggest that domains of the receptor required for inhibition of apoptosis are necessary but not sufficient for transformation.

Full Text

The Full Text of this article is available as a PDF (242.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barres B. A., Schmid R., Sendnter M., Raff M. C. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development. 1993 May;118(1):283–295. doi: 10.1242/dev.118.1.283. [DOI] [PubMed] [Google Scholar]
  2. Baserga R., Sell C., Porcu P., Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif. 1994 Feb;27(2):63–71. doi: 10.1111/j.1365-2184.1994.tb01406.x. [DOI] [PubMed] [Google Scholar]
  3. Bennett M. R., Evan G. I., Newby A. C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res. 1994 Mar;74(3):525–536. doi: 10.1161/01.res.74.3.525. [DOI] [PubMed] [Google Scholar]
  4. Bhatavdekar J. M., Patel D. D., Chikhlikar P. R., Mehta R. H., Vora H. H., Karelia N. H., Ghosh N., Shah N. G., Suthar T. P., Neema J. P. Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma. 1994;41(2):101–103. [PubMed] [Google Scholar]
  5. Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 1992 Oct 8;359(6395):552–554. doi: 10.1038/359552a0. [DOI] [PubMed] [Google Scholar]
  6. Chittenden T., Flemington C., Houghton A. B., Ebb R. G., Gallo G. J., Elangovan B., Chinnadurai G., Lutz R. J. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995 Nov 15;14(22):5589–5596. doi: 10.1002/j.1460-2075.1995.tb00246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chittenden T., Harrington E. A., O'Connor R., Flemington C., Lutz R. J., Evan G. I., Guild B. C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature. 1995 Apr 20;374(6524):733–736. doi: 10.1038/374733a0. [DOI] [PubMed] [Google Scholar]
  8. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994 Jun 2;369(6479):414–418. doi: 10.1038/369414a0. [DOI] [PubMed] [Google Scholar]
  9. Cleveland J. L., Ihle J. N. Contenders in FasL/TNF death signaling. Cell. 1995 May 19;81(4):479–482. doi: 10.1016/0092-8674(95)90068-3. [DOI] [PubMed] [Google Scholar]
  10. Coppola D., Ferber A., Miura M., Sell C., D'Ambrosio C., Rubin R., Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 1994 Jul;14(7):4588–4595. doi: 10.1128/mcb.14.7.4588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol. 1995 Jul;164(1):214–221. doi: 10.1002/jcp.1041640126. [DOI] [PubMed] [Google Scholar]
  12. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  13. Fanidi A., Harrington E. A., Evan G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature. 1992 Oct 8;359(6395):554–556. doi: 10.1038/359554a0. [DOI] [PubMed] [Google Scholar]
  14. Foekens J. A., Portengen H., van Putten W. L., Trapman A. M., Reubi J. C., Alexieva-Figusch J., Klijn J. G. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):7002–7009. [PubMed] [Google Scholar]
  15. Grønborg M., Wulff B. S., Rasmussen J. S., Kjeldsen T., Gammeltoft S. Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. J Biol Chem. 1993 Nov 5;268(31):23435–23440. [PubMed] [Google Scholar]
  16. Guo Y. S., Narayan S., Yallampalli C., Singh P. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology. 1992 Apr;102(4 Pt 1):1101–1108. [PubMed] [Google Scholar]
  17. Gustafson T. A., He W., Craparo A., Schaub C. D., O'Neill T. J. Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol Cell Biol. 1995 May;15(5):2500–2508. doi: 10.1128/mcb.15.5.2500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994 Jul 15;13(14):3286–3295. doi: 10.1002/j.1460-2075.1994.tb06630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hongo A., D'Ambrosio C., Miura M., Morrione A., Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene. 1996 Mar 21;12(6):1231–1238. [PubMed] [Google Scholar]
  20. Kaiser U., Schardt C., Brandscheidt D., Wollmer E., Havemann K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol. 1993;119(11):665–668. doi: 10.1007/BF01215985. [DOI] [PubMed] [Google Scholar]
  21. Kaleko M., Rutter W. J., Miller A. D. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990 Feb;10(2):464–473. doi: 10.1128/mcb.10.2.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kato H., Faria T. N., Stannard B., Roberts C. T., Jr, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem. 1993 Feb 5;268(4):2655–2661. [PubMed] [Google Scholar]
  23. LeRoith D., Werner H., Beitner-Johnson D., Roberts C. T., Jr Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995 Apr;16(2):143–163. doi: 10.1210/edrv-16-2-143. [DOI] [PubMed] [Google Scholar]
  24. Li S., Ferber A., Miura M., Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem. 1994 Dec 23;269(51):32558–32564. [PubMed] [Google Scholar]
  25. Li S., Resnicoff M., Baserga R. Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem. 1996 May 24;271(21):12254–12260. doi: 10.1074/jbc.271.21.12254. [DOI] [PubMed] [Google Scholar]
  26. Littlewood T. D., Hancock D. C., Danielian P. S., Parker M. G., Evan G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995 May 25;23(10):1686–1690. doi: 10.1093/nar/23.10.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Macaulay V. M., Everard M. J., Teale J. D., Trott P. A., Van Wyk J. J., Smith I. E., Millar J. L. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 1990 Apr 15;50(8):2511–2517. [PubMed] [Google Scholar]
  28. Miura M., Li S., Baserga R. Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res. 1995 Feb 1;55(3):663–667. [PubMed] [Google Scholar]
  29. Miura M., Surmacz E., Burgaud J. L., Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem. 1995 Sep 22;270(38):22639–22644. doi: 10.1074/jbc.270.38.22639. [DOI] [PubMed] [Google Scholar]
  30. Moody T. W., Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 1993;52(14):1161–1173. doi: 10.1016/0024-3205(93)90098-n. [DOI] [PubMed] [Google Scholar]
  31. Nakanishi Y., Mulshine J. L., Kasprzyk P. G., Natale R. B., Maneckjee R., Avis I., Treston A. M., Gazdar A. F., Minna J. D., Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul;82(1):354–359. doi: 10.1172/JCI113594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Neff N. T., Prevette D., Houenou L. J., Lewis M. E., Glicksman M. A., Yin Q. W., Oppenheim R. W. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol. 1993 Dec;24(12):1578–1588. doi: 10.1002/neu.480241203. [DOI] [PubMed] [Google Scholar]
  33. O'Neill T. J., Craparo A., Gustafson T. A. Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system. Mol Cell Biol. 1994 Oct;14(10):6433–6442. doi: 10.1128/mcb.14.10.6433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pollak M. N., Perdue J. F., Margolese R. G., Baer K., Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 1987 Dec;38(1-2):223–230. doi: 10.1016/0304-3835(87)90218-7. [DOI] [PubMed] [Google Scholar]
  35. Remacle-Bonnet M. M., Culouscou J. M., Garrouste F. L., Rabenandrasana C., Marvaldi J. L., Pommier G. J. Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line. J Clin Endocrinol Metab. 1992 Aug;75(2):609–616. doi: 10.1210/jcem.75.2.1322432. [DOI] [PubMed] [Google Scholar]
  36. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H. L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995 Jun 1;55(11):2463–2469. [PubMed] [Google Scholar]
  37. Resnicoff M., Burgaud J. L., Rotman H. L., Abraham D., Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res. 1995 Sep 1;55(17):3739–3741. [PubMed] [Google Scholar]
  38. Rodriguez-Tarduchy G., Collins M. K., García I., López-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 1992 Jul 15;149(2):535–540. [PubMed] [Google Scholar]
  39. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 1995 Jan 15;55(2):303–306. [PubMed] [Google Scholar]
  40. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994 Jun;14(6):3604–3612. doi: 10.1128/mcb.14.6.3604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Surmacz E., Sell C., Swantek J., Kato H., Roberts C. T., Jr, LeRoith D., Baserga R. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp Cell Res. 1995 May;218(1):370–380. doi: 10.1006/excr.1995.1168. [DOI] [PubMed] [Google Scholar]
  42. Tartare-Deckert S., Sawka-Verhelle D., Murdaca J., Van Obberghen E. Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system. J Biol Chem. 1995 Oct 6;270(40):23456–23460. doi: 10.1074/jbc.270.40.23456. [DOI] [PubMed] [Google Scholar]
  43. Ullrich A., Gray A., Tam A. W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503–2512. doi: 10.1002/j.1460-2075.1986.tb04528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Valentinis B., Baserga R. The IGF-I receptor protects tumor cells from apoptosis induced by high concentrations of serum. Biochem Biophys Res Commun. 1996 Jul 16;224(2):362–368. doi: 10.1006/bbrc.1996.1034. [DOI] [PubMed] [Google Scholar]
  45. Vaux D. L., Cory S., Adams J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988 Sep 29;335(6189):440–442. doi: 10.1038/335440a0. [DOI] [PubMed] [Google Scholar]
  46. Yee D., Paik S., Lebovic G. S., Marcus R. R., Favoni R. E., Cullen K. J., Lippman M. E., Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989 Mar;3(3):509–517. doi: 10.1210/mend-3-3-509. [DOI] [PubMed] [Google Scholar]

Articles from Molecular and Cellular Biology are provided here courtesy of Taylor & Francis

RESOURCES